Kidney Cancer Diagnostics and Therapeutics Industry Analysis Report 2 April.2017 | Página 2

Global Kidney Cancer Diagnostics Market According to the report "Kidney Cancer Diagnostics and Therapeutics Market ", published by Market Data Forecast, the global market is projected to reach USD 4.09 billion by 2021, at a CAGR of 5.64% from 2016 to 2021. Kidney cancer is one of the frequent urologic tumours accounting for around 3% of all human cancers. Surgical methods alone are sometimes not enough for the treatment of these cancers, mainly in cases where patients acquire metastatic cancers. This is when supplementary treatment routines are suggested and various factors such as immunotherapies and targeted therapies come into equation. The growth of the Global Kidney Cancer Diagnostics and Therapeutics Market is mainly driven by factors such as rising aging population, Changes in lifestyle such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for kidney Cancer. Global Market for Kidney Cancer Diagnostics and Therapeutics is segmented based on Type, Tests and Region into further sub-segments as follows: 1) Based on Type:     Transitional Cell Cancer Renal cell carcinoma Renal sarcoma Others 2) Based on Tests:      Biopsy CT Scan Cystoscopy Intravenous pyelogram Kidney Ultrasound 3) Geographical Segmentation:      North America Europe Asia-Pacific Latin America Middle East and Africa The major companies dominating the Kidney Cancer Diagnostics and Therapeutics market are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, Abbott Laboratories. TABLE OF CONTENTS 1. Introduction 1.1 Market Definition 1.2 Study Deliverables 1.3 Base Currency, Base Year and Forecast Periods [phone] | www.marketdataforecast.com | [email protected]